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Surgical outcomes are closely related to the appropriate choice
of the right procedure and its timing, the patient’s risk and tech-
nical proficiency. It is generally recognized that these 3 factors
contribute more or less equally to the final result [1]. However,
early and late outcomes of surgery are also influenced, among
other factors, by active prevention of complications, through
pharmacological strategies and optimized blood management
[2]. Indeed, although surgeons are mostly focused on performing
the most technically challenging procedures, the role of medica-
tion is often underestimated. A coronary artery bypass grafting
operation can be a great technical success, but if a patient suffers
a mediastinitis because antibiotic prophylaxis was not adminis-
tered correctly, he/she will not consider the operation to be very
helpful. This is also the case if the patient progresses into heart
failure because beta-blockers, angiotensin-converting enzyme
inhibitors and antiplatelet agents have not been prescribed to
induce left ventricular remodelling and improve graft patency [3].
The European Association for Cardio-Thoracic Surgery (EACTS)
guidelines committee and council have decided that perioperative
medication in adult cardiac surgery and patient blood manage-
ment (PBM) are important topics for which there is a sufficient
body of evidence to be summarized in comprehensive guidance
for cardiothoracic surgeons, anaesthesiologists and allied health
professionals. Using the EACTS methodology for guideline devel-
opment, both guidelines were based on the core principle that
evidence gathering and its grading is independently performed by
methodologists, while a multidisciplinary task force is responsible
for writing recommendations based on the evidence synthesis [4].
It is important to note that a close collaboration between method-
ologists and task force members is necessary to produce the most
appropriate and evidence-based recommendations. Another key
feature of the 2 guidelines is that both task forces included a multi-
disciplinary group of specialists involved with the perioperative
care of cardiac surgery patients. Thus, the 2017 guidelines on PBM
were jointly produced by a task force composed of experts from
the EACTS and European Association for Cardiothoracic
Anaesthesia (EACTA) [5], while the 2017 guidelines on
perioperative medication in adult cardiac surgery were co-chaired
by a cardiologist and included, in addition to cardiac surgeons, 2
cardiologists and 1 anaesthesiologist [6]. Both measures were
employed to increase the credibility and trustfulness of these
guidelines [7]. As with many other aspects of surgical management,
the level of evidence of many recommendations is based on
observational studies and expert opinions. However, the opinion
of experts continues to be valued by clinicians although should
not prevent the personal assessment of the recommendations. We
should not forget that even when randomized trials support rec-
ommendations, the final decision is always the responsibility of
the treating physician, as trial results often apply to selected popu-
lations that may differ from the specific patient.
Perioperative medication in adult cardiac surgery, in its largest
sense, is a vast subject that is hard to embrace in a single docu-
ment. The task force has included the most common medications
used in patients undergoing cardiac surgery, excluding those uti-
lized to specifically treat complications, such as pneumonia. One
can argue whether drugs used to treat low cardiac output or
myocardial ischaemia should have been included, but these
topics have been addressed in other publications. We do believe
that common complications following cardiac surgery should be
covered in separate comprehensive guidelines and expert opin-
ion documents, where the task forces also include medical pro-
fessionals from other specialities. The perioperative medication
guideline has been subdivided into preoperative, intraoperative
and postoperative medications [6]. Clear recommendations are
provided on (i) when specific types of antiplatelet and anticoagu-
lation (including both vitamin K antagonists therapy and new
oral anticoagulants) should be discontinued or continued before
surgery and when to restart these postoperatively, (ii) the initia-
tion of statins preoperatively, (iii) when antihypertensive medica-
tion should be stopped preoperatively and its role in long-term
secondary prevention; (iv) the use, timing and dosing of prophy-
lactic antibiotics; (v) prophylactic administration of steroids;
(vi) preoperative and postoperative use of beta-blockers; (vii) gly-
caemia control in the intensive care unit and on the ward; (viii)
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different modalities of pain relief medication; and (ix) lipid-
lowering therapies as secondary prevention. Importantly, the rec-
ommendations include crucial nuances in the use of these
medications.
The new guidelines on blood management incorporate the
recent evidence on the blood conservation interventions while
continuing to emphasize the importance of teamwork between
the surgeons, anaesthesiologists and clinical perfusionist to mini-
mize bleeding and bleeding complications [5]. The authors have
covered the entire perioperative period and divided the guide-
lines into preoperative optimization, intraoperative interventions
and treatment of postoperative bleeding disorders.
The preoperative evaluation includes (i) identification of
patients at high risk for postoperative bleeding, (ii) preoperative
haemoglobin optimization through the identification and treat-
ment of anaemia and (iii) the management of patients on antith-
rombotic therapy with laboratory assessment: which test and if
so, why? Furthermore, the guideline recommends several blood
conservation measures in cardiac operations: (i) the limitation of
haemodilution during cardiopulmonary bypass with the use of
retrograde and anterograde autologous priming, (ii) the routine
use of cell salvage systems, (iii) heparin level over the convention-
ally used activated clotting time-guided heparin management
especially in patients who are heparin resistant, (iv) dose of prot-
amine sulphate in a protamine-to-heparin dosing ratio lower
than 1:1 based on the initial given heparin dose and (v) preoper-
ative autologous blood and acute normovolaemic haemodilution
donation to preserve blood components. On the other hand,
several interventions such as the routine use of topical sealants,
antithrombin supplementation in bleeding patients, the use of
goal-directed haemodynamic therapy and the use of low-
molecular-weight starches are not recommended. Importantly,
these measures are likely to be most effective when incorporated
in a hospital protocol. Concern regarding fluid overload is justi-
fied, but the successful limitation of haemodilution requires close
collaboration between the anaesthesia team and the perfusionist.
Finally, procoagulant interventions and transfusion strategies
close the circle of PBM in cardiac surgery. The guideline recom-
mends the routine use of antifibrinolitic therapy if there are no
contraindications, but other procoagulant interventions including
the use of fibrinogen concentrate and recombinant factor VIIa
are indicated only in selected cases. The authors have agreed
with the European Medicines Agency [8] that the benefits of
aprotinin outweigh the risk in selected patients. However, a defi-
nite answer to the question ‘which patients should receive
aprotinin’ requires further investigation through a well-designed
safety study.
Anticoagulation and antiplatelet agents have essential implica-
tions for patients undergoing cardiac surgery both preoperatively
and postoperatively as to when to stop and when to resume and
whether bridging is needed. To bring the recommendations to
the reality of clinical practice, treatment algorithms were devel-
oped separately for management of anticoagulation during the
perioperative period as well as antiplatelet therapy in patients
undergoing coronary artery bypass grafting surgery. These
treatment algorithms are examples of how to apply the recent
recommendations in a clinical context, helping clinicians in the
translation of evidence-based recommendations into daily
practice. Hence, both guidelines on the perioperative medication
in adult cardiac surgery and PBM offer strategies to improve out-
come and reduce complications in adult cardiac surgery.
However, to find out how useful these documents are, and how
they are rated by the medical community, we will need to assess
how these recommendations are implemented and how these
impact daily practices, through surveys and studies.
The objective of these guidelines is to provide helpful, easy,
quick access to essential information for the busy clinician and,
at the same time, provide the evidence to support the recom-
mendations for those wishing a more profound understanding
on these topics. Moreover, guidelines also identify areas where
evidence is lacking, which is important for future study directives.
For the first time in EACTS history, these two guidelines have
been summarized into a pocket format, in addition to the full-
text document published in European Journal of Cardio-Thoracic
Surgery (EJCTS). These pocket guidelines were shared with several
thousand colleagues during the recent EACTS annual meeting in
Vienna. Further copies can be ordered from the EACTS office.
The EACTS guidelines committee will also continue to promote
the new guidelines by supporting societies on a national level
with presentations and pocket guidelines.
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